NASDAQ:SNTI Senti Biosciences (SNTI) Stock Price, News & Analysis $2.68 +0.08 (+3.08%) (As of 10:30 AM ET) Add Compare Share Share Today's Range$2.56▼$2.7950-Day Range$1.58▼$4.1852-Week Range$1.52▼$8.48Volume18,359 shsAverage Volume301,951 shsMarket Capitalization$122.62 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Senti Biosciences alerts: Email Address Ad Behind the MarketsSecure this "AI Fuel" Stock Before the Billionaires Buy It AllAccording to the Washington Post, America is running out of a crucial component for AI. Without this "AI fuel," firms like NVIDIA would have to shut down their operations.Click here for the ticker >>> About Senti Biosciences Stock (NASDAQ:SNTI)Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Read More SNTI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SNTI Stock News HeadlinesAugust 14, 2024 | finanznachrichten.deSenti Biosciences, Inc.: Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline HighlightsAugust 14, 2024 | investorplace.comSNTI Stock Earnings: Senti Biosciences Reported Results for Q2 2024August 22, 2024 | Darwin (Ad)Top Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.August 13, 2024 | globenewswire.comSenti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline HighlightsAugust 5, 2024 | globenewswire.comSenti Bio Announces Execution of Grant Award from California Institute for Regenerative Medicines (CIRM) for Clinical Development of SENTI-202July 20, 2024 | bizjournals.comTech icon leads $125 million push to develop cancer immunotherapiesJuly 16, 2024 | globenewswire.comSenti Bio Announces Reverse Stock SplitJuly 1, 2024 | globenewswire.comSenti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell TherapyAugust 22, 2024 | Darwin (Ad)Top Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.June 25, 2024 | investorplace.comWhy Is Senti Biosciences (SNTI) Stock Up 32% Today?May 13, 2024 | finance.yahoo.comSenti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid LeukemiaMay 10, 2024 | finanznachrichten.deSenti Biosciences, Inc.: Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate HighlightsMay 10, 2024 | msn.comSenti Biosciences GAAP EPS of -$0.26May 10, 2024 | investorplace.comSNTI Stock Earnings: Senti Biosciences Reported Results for Q1 2024May 9, 2024 | globenewswire.comSenti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate HighlightsApril 30, 2024 | globenewswire.comSenti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)March 23, 2024 | finanznachrichten.deSenti Biosciences, Inc.: Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent HighlightsMarch 21, 2024 | globenewswire.comSenti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent HighlightsSee More Headlines Receive SNTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Senti Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today8/22/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SNTI CUSIPN/A CIK1854270 Webwww.sentibio.com Phone650-239-2030FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-71,060,000.00 Net MarginsN/A Pretax Margin-6,405.10% Return on Equity-79.71% Return on Assets-48.64% Debt Debt-to-Equity RatioN/A Current Ratio5.79 Quick Ratio5.79 Sales & Book Value Annual Sales$255,000.00 Price / Sales466.52 Cash FlowN/A Price / Cash FlowN/A Book Value$15.02 per share Price / Book0.17Miscellaneous Outstanding Shares45,755,000Free Float38,480,000Market Cap$118.96 million OptionableNot Optionable Beta2.74 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Timothy K. Lu M.D. (Age 43)Ph.D., Co-founder, CEO, President & Director Comp: $868.57kDr. James J. Collins Ph.D. (Age 58)Scientific Co-Founder, Chairperson of Scientific Advisory Board & Independent Director Comp: $58.5kMs. Susan D. Berland (Age 69)Senior Financial Executive & Independent Director Comp: $57.5kDr. Kanya Rajangam M.D. (Age 50)Ph.D., Head of Research & Development and Chief Medical Officer Comp: $689.99kDr. Wilson Wong Ph.D.Scientific Co-Founder & Member of Scientific Advisory BoardMr. Mike RheeSenior VP of Legal Affairs & Corporate SecretarySusan KahlertControllerMore ExecutivesKey CompetitorsGood Works II AcquisitionNASDAQ:GWIIIntelligent Medicine AcquisitionNASDAQ:IQMDCorsair PartneringNYSE:CORSVoyager TherapeuticsNASDAQ:VYGRAura BiosciencesNASDAQ:AURAView All CompetitorsInstitutional OwnershipARK Investment Management LLCSold 45,150 shares on 7/26/2024Ownership: 34.624%View All Institutional Transactions SNTI Stock Analysis - Frequently Asked Questions How have SNTI shares performed this year? Senti Biosciences' stock was trading at $6.60 on January 1st, 2024. Since then, SNTI stock has decreased by 59.4% and is now trading at $2.68. View the best growth stocks for 2024 here. When did Senti Biosciences' stock split? Senti Biosciences shares reverse split on Thursday, July 18th 2024. The 1-10 reverse split was announced on Thursday, July 18th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 18th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Senti Biosciences' major shareholders? Top institutional shareholders of Senti Biosciences include ARK Investment Management LLC (34.62%). View institutional ownership trends. How do I buy shares of Senti Biosciences? Shares of SNTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SNTI) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredThis Crypto Is Set to Explode in AugustWith the 2024 Bitcoin Halving, there's a potential HUGE bull run for altcoins. While everyone's chasing the...Crypto 101 Media | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredSilver Grab of the Decade?In a groundbreaking move, J.P. Morgan now possesses the largest amount of physical silver in recorded history…...Colonial Metals | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredThis One stock is all you need...What if you could ignore 99% of the stock market... And retire on just ONE ticker?Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Senti Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Senti Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
